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Background: Caseous lymphadenitis (CLA) is an infectious disease that affects small ruminants and is caused by
Corynebacterium pseudotuberculosis. This disease is responsible for high economic losses due to condemnation and
trim of infected carcasses, decreased leather and wool yield, loss of sales of breeding stock and deaths from
internal involvement. Treatment is costly and ineffective; the most cost-effective strategy is timely immunisation.
Various vaccine strategies have been tested, and recombinant vaccines are a promising alternative. Thus, in this
study, different vaccine formulations using a recombinant protein (rCP40) and the CP09 live recombinant strain
were evaluated. Five groups of 10 mice each were immunised with saline (G1), rCP40 (G2), CP09 (G3), a combination of
CP09 and rCP40 (G4) and a heterologous prime-boost strategy (G5). Mice received two immunisations within 15 days.
On day 30 after primary immunisation, all groups were challenged with a C. pseudotuberculosis virulent strain. Mice were
monitored and mortality was recorded for 30 days after challenge.
Results: The G2, G4 and G5 groups showed high levels of IgG1 and IgG2a; G2 presented significant IgG2a production
after virulent challenge in the absence of IgG1 and IgG3 induction. Thirty days after challenge, the mice survival rates
were 20 (G1), 90 (G2), 50 (G3), 70 (G4) and 60% (G5).
Conclusions: rCP40 is a promising target in the development of vaccines against caseous lymphadenitis.
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Caseous lymphadenitis (CLA) is an infectious, chronic
and subclinical disease of sheep and goats with a world-
wide occurrence [1,2]. CLA is characterised by the for-
mation of subcutaneous abscesses in lymph nodes or as
a subclinical infection in internal organs, such as the
lungs, liver and kidneys [3]. The etiologic agent of CLA
is Corynebacterium pseudotuberculosis, a gram-positive,
non-spore-forming, aerobic and facultative intracellular
parasite of macrophages [3]. CLA is responsible for
significant economic losses in the sheep and goat indus-
tries due to its high incidence, causing condemnation of* Correspondence: vascoariston@gmail.com
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unless otherwise stated.carcasses, devaluation of leather due to scars left by
abscesses, decreased production of meat or milk, and
occasional death of affected animals [4,5].
CLA commercial vaccines are based on attenuated
strains of C. pseudotuberculosis and do not provide satis-
factory protection for goats. Additionally, annual boosters
are needed, which makes prophylaxis more costly [6].
Thus, the search for an ideal CLA vaccine has been priori-
tised, with the aim of obtaining long-lasting protection
with few side effects. Additionally, the vaccine should
allow the differentiation between vaccinated and infected
animals [1].
Pursuing this purpose, different vaccine strategies
have been tested, and live attenuated vaccines and re-
combinant proteins are promising options. Through a
process of random mutagenesis, it was identified 34 liveis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which (CZ171049, now called CP09) presented promising
results in pilot trials, where inoculated mice presented no
clinical signs of caseous lymphadenitis and produced a
significant amount of specific IgG.
The serine protease CP40, encoded by the cp40 gene
of C. pseudotuberculosis, was tested in infected animals
and demonstrated immunogenic properties, showing a
strong humoral response on immunoblots and a 82%
reduction in the proportion of infected sheep and a 98%
reduction in lung lesions [8]; these protection levels
were similar to those found with other immunogens, as
inactivated bacteria and genetically detoxified phospho-
lipase D [9,10].
Considering the need for new immunogens for caseous
lymphadenitis prophylaxis and the promising results
already found with the mutant CP09 strain and the re-
combinant CP40 protein (rCP40), the aim of this work is
to perform a comparative evaluation of four vaccine
formulations containing these immunogens alone or
in combination, and determine their ability to induce
immunoprotection against caseous lymphadenitis in a
murine model.
Methods
C. pseudotuberculosis strains and culture conditions
The previously obtained C. pseudotuberculosis CP09
mutant strain [7], the T1 pathogenic wild-type paren-
tal strain [11], and the caprine-pathogenic strain
MIC-6 from the Laboratory of Genetics and Control
of Microorganisms (Belo Horizonte, Brazil) bacterial
collection were employed in this work. Strains were
aerobically grown in “Brain Heart Infusion” broth
(BHI, Oxoid) at 37°C. Kanamycin (kanamycin sulphate
25 μg/mL; Sigma-Aldrich, USA) was added to the
mutant growth media. T1 and MIC-6 strains were
isolated from caseous lesions of goats and have previously
been employed in vaccination trials using goats and
mice [11,12].
Bacterial interaction assays with murine J774 cells
Pre-macrophagic J774 cells from murine lymphomas
were cultivated in Dulbecco’s modified Eagle’s essential
medium (DMEM, Sigma-Aldrich, USA) supplemented
with 5% foetal bovine serum, 50 μg/mL gentamicin and
2.5 μg/mL fungizone at 37°C in a 5% CO2 atmosphere.
The CP09 mutant strain and T1 wild-type strain were
grown for 48 hours at 37°C and washed three times
with PBS, resuspended in DMEM to a concentration
of 106 CFU/mL, and used to infect J774 cells (multiplicity
of infection [MOI]: 10 bacteria: 1 cell) grown to approxi-
mately 95% confluence in 24-well tissue culture plates.
For determination of intracellular viable bacteria, after
1, 3 and 6 hours of incubation, infected J774 monolayerswere washed six times with PBS and treated with
150 μg/mL gentamicin sulphate (Sigma-Aldrich, USA)
diluted in DMEM for 1 h. The number of intracellular
bacteria was determined by viable counts after lysis of
monolayers with 0.5 mL of 0.1% TritonX-100 (Sigma-
Aldrich, USA) in PBS.DNA extraction and PCR reaction
C. pseudotuberculosis genomic DNA was obtained from
the T1 strain as previously described [13]. Briefly,
5.0 mL of the bacteria cultured in BHI broth was centri-
fuged and resuspended in 50 mM EDTA with 10 mg/mL
lysozyme, and the Wizard® Genomic DNA Purification
Kit (Promega, EUA) was used following the manufac-
turer’s instructions. After DNA extraction, the material
was resolved by electrophoresis on a 1.0% agarose gel and
quantified. Eluted DNA was stored at −20°C pending PCR
amplification.
PCR was performed using the Go Taq® Green Master
Mix Kit (Promega, EUA), with the objective to amplify
the cp40 gene (accession number NC_014329.1NCBI).
The primers used in the PCR assay were CP40F (5´
CGCGGATCCATGCATAATTCTCCTCGATCAG 3’) and
CP40R (5’ CGGGAATTCTTATCTAG AACCAGTTGGC
TTTC 3’), which contain BamHI and EcoRI restriction
sites, respectively. Each PCR reaction had a final volume of
50 μL, with 25 μL from the kit, 1 μL of each primer
(100 μM), 22 μL of ultra-purified water and 1 μL of
genomic DNA from C. pseudotuberculosis strain T1. The
amplification reaction consisted of an initial denaturation
step at 94°C for 2 min, 35 cycles of denaturation for 1 min
at 94°C, primer hybridisation for 1 min at 55°C and exten-
sion at 72°C for 1.5 min, followed by a final extension at
72°C for 10 min. The reaction was conducted in a thermo-
cycler (Mastercycler Gradient, Eppendorf, Germany), and
the final product was analysed by electrophoresis on a 1%
agarose gel with GelRed™ (Biotium, USA) staining.Cloning and recombinant protein production and
purification
Cloning, recombinant protein production and protein
purification were performed as previously described [13].
The pAE vector [14] and the amplified cp40 gene were
digested using BamHI and EcoRI restriction enzymes
(Fermentas, USA). After that, the cp40 gene was inserted
into the pAE vector using the T4 DNA ligase enzyme
(Fermentas, USA), and electrocompetent TOP 10 E. coli
cells were transformed by electroporation. The transfor-
med bacteria were cultivated in Luria-Bertani (LB) broth
with 100 μg/mL ampicillin for 16 h, and the recombinant
plasmid was purified using a MiniPrep Kit (Qiagen, USA).
The pAE/CP40 recombinant plasmid was transformed
by thermal shock in E. coli BL21, and the recombinant
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IPTG for 3 h at 37°C in an orbital shaker.
For recombinant protein purification, the bacteria
resulting from a large-scale culture (500 mL) were pelleted
by centrifugation and resuspended in a washing buffer
(200 mM NaH2PO4; 500 mM NaCl, 5 mM Imidazole;
8 M Urea pH 8.0) with 100 mg/mL lysozyme, sonicated
five times for fifteen seconds (20 KHz) and maintained
under agitation at 4°C for 16 h. The recombinant protein
was purified using the HisTrapTM HP (GE Healthcare,
USA) affinity chromatography column followed by dialysis
in a cellulose tube-based system (Sigma, USA).Animal model
Six- to eight-week-old BALB/c mice, a strain which is
susceptible to C. pseudotuberculosis infection [1], were
employed in this assay. For immunity tests, fifty mice
were kept in a vivarium under suitable conditions of tem-
perature and humidity with a 12 h light/dark cycle; food
and water were provided ad libitum. The study was ap-
proved by the Ethics Committee for Animal Experimen-
tation of the Tiradentes University (protocol number
010413).Immunisation protocol, challenge and determination of
the protection level
The rCP40 recombinant protein and CP09 live recom-
binant strain were used in vaccine formulations. Animals
were divided into five groups (n = 10 each) and immu-
nised intraperitoneally (i.p.) and/or subcutaneously (s.c.)
on days 0 and 15. The administration routes followed
what was previously described for recombinant proteins
and mutant strains immunisation protocols [7,8,10].
The negative control group (G1) was inoculated i.p. with
100 μL of saline solution (0.9% NaCl). The G2 group was
inoculated i.p. with 200 μL of a solution containing rCP40
(50 μg) and saponin (7.5 μg) in sterile saline solution. G3
was inoculated s.c. with 100 μL of the CP09 recombinant
live strain (106 CFU). G4 was inoculated i.p. with 200 μL
of a solution containing rCP40 (50 μg) and saponin
(7.5 μg) and s.c. with 100 μL of the recombinant live CP09
strain (106 CFU). Group G5 used a heterologous prime-
boost strategy and was first inoculated i.p. with 200 μL of
rCP40 (50 μg) and saponin (7.5 μg) in solution followed
by an s.c. booster dose of 100 μL of the live recombinant
strain CP09 (106 CFU) 15 days after the first vaccination.
The previously immunised animals were challenged
with 104 CFU/mL (i.p.) of the MIC-6 virulent strain
thirty days after the last immunisation. The protection
conferred was assessed according to the survival rate of
the animals immunised with different vaccine formula-
tions. The animals were observed daily, and mortality was
recorded over four weeks following the challenge.Blood collection and ELISA for specific IgG determination
Animals were bled at days 0, 15, 30, 45 and 60 post-
immunisation to determine the antibody levels. Blood
was collected from the retro-orbital sinus with Pasteur
pipettes. All blood collections were performed under an-
aesthesia with ketamine 10% (1 mL/kg) and xylazine 2%
(0.1 mg/kg) (Agener União Saúde Animal, Brazil), and
all efforts were made to minimise suffering. After coagula-
tion, blood was centrifuged at 1,500 g for 10 min. Serum
was removed and stored at −20°C.
Sera samples from the immunised mice were used in
immunoassays (ELISA) for detection of specific IgG1,
IgG2a and IgG3 antibodies. For this purpose, polystyrene
96-well plates (Greiner, USA) were coated with 100 μL
of C. pseudotuberculosis T1 strain supernatant diluted
1:100 [15] (for G3 sera samples) or 0.125 ug/mL of rCP40
(for G2 sera samples) or a combination of both antigens
(for G4 and G5 sera samples). All antigen dilutions were
made in bicarbonate-carbonate buffer (pH 9.6). Plates
were incubated at 4°C for 18 h. After this period, plates
were washed twice with PBS-T (1X PBS, pH 7.4, 0.05%
Tween 20) and blocked with 200 μL/well of 5% defatted
milk in PBS-T for 2 h at 37°C. After this blocking step, the
wells were washed five times with PBS-T and then
100 μL/well of sera samples from mice diluted 1:100 in
PBS-T were added in duplicate. After one hour of incuba-
tion at 37°C and five washes with PBS-T, 50 μL/well of an
anti-mouse antibody against IgG1, IgG2a or IgG3 (Invitro-
gen Life Technologies, USA) diluted 1:5000 was added.
The plates were again incubated for 45 min at 37°C and
then washed five times with PBS-T. After the washes,
50 μL/well of TMB developing solution (10 mL citric-
phosphate buffer pH 5.1, 4 mg of orthophenylenediamine,
4 μL of H2O2) was added. The reaction was stopped by
adding 25 μL of 4 N H2SO4. The absorbance was mea-
sured at 450 nm using an ELISA reader (Thermo Plate TP
Reader, Thermo, USA).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism version 6.0 for Windows (GraphPad Software,
USA). The results of intracellular viability and specific
immunoglobulins production were expressed as the
means ± standard deviations. Differences between IgG
production in the different groups were calculated by
one-way ANOVA followed by the Tukey post-test test.
The data were considered statistically significant when
p < 0.05.
Results
Bacterial interaction assays with murine J774 cells
Analysing the results presented in Figure 1, it can be
observed that the mutation harboured by the CP09 mu-
tant had a major influence on the ability of this strain to
Figure 1 Cellular invasion pattern of C. Pseudotuberculosis
strain CP09 after 1, 3 and 6 hours of interaction with J774 cells.
The results are expressed as the means ± standard deviation of two
representative experiments performed in quadruplicate. ***Significant
reduction of cellular invasion versus T1 wild-type (wt) strain cellular
invasion ; p < 0.5 (ANOVA, Tukey).
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the rate of CP09 cell invasion in J774 cells was only 20%
of the rate of cellular invasion achieved by the T1 paren-
tal strain at the same time point.
Evaluation of the IgG levels
Immunisations with the combination of rCP40 and
CP09 induced the production of IgG1 in all immunised
groups, as shown in Figure 2a. The results demonstrated
that all groups on days 0 and 15 post-immunisation (p.i.)
showed no significant IgG1 production (p > 0.05). On
day 30, the G2, G4 and G5 groups showed significantly
higher levels of IgG1 than groups G1 and G3 (p < 0.05).
On days 45 and 60, after the challenge with the virulent
strain, G4 and G5 groups showed significantly higher
concentrations of IgG1 than the control and G3 groups
(p < 0.05). No significant IgG1 production was observed
in the G2 group after challenge.
Figure 2b shows the results obtained from the ELISA
assay for the analysis of IgG2a production. On day 30
p.i., G2, G4 and G5 groups showed significantly higher
concentrations of IgG2a (p <0.05) than groups G1 and
G3. The same trend was observed in these groups after
the MIC-6 strain challenge at 45 and 60 days p.i..
No significant IgG3 production was observed in
any group, either before or after the virulent challenge
(Figure 2c).
Determination of protection levels
The survival curve of mice immunised with vaccine
formulations and challenged with C. pseudotuberculosis
strains is presented in Figure 3. The animals were evalu-
ated for thirty days after the challenge. In these trials, 10
mice in each group were monitored daily, and mortality
events were recorded. Animals from the G2, G3, G4,
and G5 groups showed, respectively, 90, 50, 70 and 60%survival 30 days after infection with the C. pseudotuber-
culosis MIC-6 wild strain.
Discussion
Recombinant proteins and live attenuated vaccines are
considered promising tools for the development of new
vaccine models. In this regard, Dorella et al. [7], using a
reporter transposon-based system, identified 34 out of
1,500 mutants that presented detectable alkaline phos-
phatase (PhoZ) activity. This feature was associated with
21 C. pseudotuberculosis loci that encode fimbrial and
transport proteins. One of these mutants, CZ171049
(now called CP09) showed promising protective results
in pilot trials and was suggested for further investigation
in attenuation and immunisation-challenge trials.
In this study, we conducted a cellular adhesion experi-
ment to observe how the mutation in the CP09 strain
affected its capacity to adhere and infect murine macro-
phage cells. The results showed a significantly reduced
capacity for cell adhesion and invasion, corroborating
the genetic fimbrial mutant profile previously observed
by Dorella et al. [7]. Clayton et al. [16] observed that
mutations in Salmonella enterica fimbrial subunits
genes led to reduced intestinal colonisation in chickens.
Additionally, work by van der Velden et al. [17] showed
that multiple fimbrial adhesions are required for a fully
virulent profile in a murine model of Salmonella typhi-
murium infection. This attenuated cellular adhesion
profile was confirmed for the C. pseudotuberculosis CP09
strain, and other experiments were conducted with the
objective of determining the immunogenicity and protect-
ive potential of this mutant in a caseous lymphadenitis
model in mice.
The development of cellular and humoral immune
responses depends on the set of cytokines produced by
various cells, including CD4+ and CD8+ T cells. When a
naive T helper (Th) cell is activated by dendritic cells, it
can differentiate into one of three distinct types of ef-
fector Th cells called T helper 1 (Th1), 2 (Th2) and 17
(Th17). Th1 cells are mainly involved in immunity
against intracellular pathogens, and aid in the activation
of macrophages and cytotoxic T cells and the production
of opsonising and complement activator immunoglobulin
isotypes, such as IgG2a in mice. Th2 cells are involved pri-
marily in immunity against extracellular pathogens, such
as multicellular parasites, and assist B cells in producing
neutralising antibodies (IgG1 and IgG3) [18,19].
Based on the results presented herein, the G2 (rCP40),
G4 (rCP40 + CP09) and G5 (prime-boost) groups had a
very significant induction of IgG1, mainly from day 30
after the start of the trail. The G2 group did not presented
presented significant IgG1 levels after the challenge (45
and 60 days after primary immunisation). These results
suggest that the groups treated with inoculation solutions
Figure 2 Total specific IgG isotype levels in immunised mice with different vaccine formulations. The sera of immunised mice were
collected 0, 15, 30, 45, and 60 days post-immunisation and tested by ELISA for the presence of specific IgG1 (A), IgG2a (B) and IgG3 (C). The
results are presented as the means and standard deviation (bars) for each experiment with ten animals per group. Significant differences between
IgG production in the different groups was calculated employing one-way ANOVA followed by the Tukey post-test. D,d: groups significantly
different on day 30 (p < 0.05); E,e: groups significantly different on day 45 (p < 0.05); F,f: groups significantly different on day 60 (p < 0.05). Arrows
correspond to the two immunisations (days 0 and 15), and stars indicate the challenge with the virulent strain (Day 30). All bleedings were performed
before immunisations and challenge.
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sponse mediated by Th2 lymphocytes, as can be indicated
by significant IgG1 production [20].Although the protective role of IgG2a in this disease
model is largely unknown, this IgG subtype is thought to
modulate the immune response by inducing phagocytosis
Figure 3 Graphical representation of the survival of immunised mice after virulent challenge. The data show the results of an experiment
using 10 mice per group. Survival was monitored for 30 days after challenge.
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plement system and cytotoxicity mediated by antibody-
dependent cells. IgG2a production requires the induction
of IFN-gamma by Th1 and NK cells [21-23]. Our results
indicate that G2, G4 and G5 groups presented significant
IgG2a production thirty days after the first immunisation,
with a perceptible boost in its concentration after chal-
lenge with the recombinant strain; the group inoculated
with the CP09 mutant strain alone was not able to pro-
duce specific IgG2a. Thus, significant IgG2a production in
the above groups demonstrates the ability of the rCP40-
saponin formulation to generate a Th1 adaptive immune
response and memory. The Th1 immune response is
responsible for the elimination of intracellular pathogens
such as C. pseudotuberculosis [24], suggesting that the
type of response induced in animals inoculated with the
recombinant protein is consistent with the immune activ-
ity responsible for the control of intracellular bacteria.
According to Marini et al. [25], immune responses
with high levels of IgG1, IgG2a and IgG3 in the serum
are important mechanisms that help eliminate microor-
ganisms. This indicates that our results are promising
for the development of an effective vaccine against CLA.
Vaccine formulations used in G2 (rCP40), G4 (rCP40 +
CP09) and G5 (heterologous prime-boost) groups showed
more significant results with respect to the level of specific
immunoglobulins generated against rCP40, a recombinant
protein that is considered to be an important C. pseudotu-
berculosis virulence factor in genomic and bioinformatics
surveys [26].
A 90% protection rate was obtained in animals immu-
nised with rCP40 alone, which is consistent with earlier
work from Walker et al. [8]. These authors used the
native semi-purified CP40 to evaluate antibody levels
generated before and after infection in sheep and ob-
served that this native 40 KDa protein provided an 82%protection rate, significantly reducing lung lesions. The
protection in animals immunised only with CP09 mu-
tant strain resulted in 50% survival after virulent chal-
lenge, which is in agreement with previously published
results [7]. Ribeiro et al. [12] described a high protection
rate (80%) in a murine model when using an iron
acquisition-deficient mutant obtained with the same
methodology employed to develop the CP09 mutant,
showing that C. pseudotuberculosis live attenuated mu-
tants can be promising tools for protection against case-
ous lymphadenitis.
Animals in groups G4 (CP09 + rCP40) and G5 (prime-
boost) had survival rates of 70 and 60%, respectively.
These two vaccine formulations had not been previously
tested, so there is no work in the literature describing
aspects of survival. After evaluating the results, it was
observed that the survival rates of these groups were
intermediate compared with those found in the G2 and
G3 groups, which were vaccinated with only rCP40 (90%
survival) and CP09 (50% survival), respectively.
The fact that CP40 recombinant protein alone led to a
protection rate of 90% whereas the combination of
rCP40 and CP09 mutant showed only a 70% protection
can be explained by a differential complexation of the
CP40 protein with the saponin adjuvant in the formula-
tion using only the recombinant protein, when com-
pared to the CP09 mutant-CP40 protein immunogen,
which can lead to a different availability of the antigen
to the immune system cells. A similar situation was seen
by Keyburn et al. [27,28] when working with vaccines to
Clostridium perfringens; they described that the protec-
tion rate achieved with the recombinant NetB protein
alone was different from the one observed with the com-
bination of the protein with the C. perfringens toxoid.
Taken together, these results suggest that vaccine for-
mulations using the recombinant protein CP40 alone or
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or both antigens used in a prime-boost strategy, result in
satisfactory survival percentages and antibody produc-
tion. However, only the groups that had rCP40 in the
inoculation solution presented an IgG2a response, and
the group inoculated only with rCP40 was not able to
induce an IgG-based humoral response, even after the
challenge. These results indicate that rCP40 was able to
induce a Th1 immune response, and the higher levels of
protection in the G2 group can be observed as a result
of this type of cellular immune response. All the groups
stimulated with the combination of rCP40 with CP09
had a significant IgG1 response, indicating a Th2 re-
sponse. The finding that the marked Th2 response elicited
a low protection rate in those groups can be explained by
the bacterial attenuation profile, which showed a reduced
capacity of the mutant to adhere and invade murine cells.
This reduced invasion can result in a defective presenta-
tion of bacterial antigens through a Major Histocompati-
bility Class (MHC) I pathway [21] because these antigens
are not present in sufficient levels in the intracellular
compartment. In this way, a Th2 response, represen-
ted by significant IgG1 production, prevailed, and the
amount of Th1 cytokines was potentially insufficient to in-
duce an adequate cellular response against the virulent C.
pseudotuberculosis strain.Conclusions
The C. pseudotuberculosis CP09 live attenuated strain was
not able to induce a humoral immune response when
inoculated alone in mice; IgG production could only be
observed when the mutant strain was combined in a vac-
cine formulation with the CP40 recombinant protein. The
protection level was higher when the vaccine solutions in-
cluded only the recombinant protein and was associated
with a Th1 response in the absence of a Th2 profile after
challenge, as seen by the IgG isotype production in immu-
nised mice. Thus, rCP40 associated with a saponin adju-
vant is a promising vaccine formulation in the control of
caseous lymphadenitis.Competing interests
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